WAYNE, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a leading global provider of medical technologies, today announced the first patient enrolled in the latest Barrigel™ rectal ...
BETHLEHEM, Pa., Nov. 7, 2025 /PRNewswire/ -- Following publication of BioProtect's pivotal randomized trial in the International Journal of Radiation Oncology, Biology, Physics (Red Journal) and ...
Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment. 1-4 Hyaluronic acid is a ...
Physicians at medical practices affiliated with Solaris Health, the nation’s leading healthcare management company in the urological field, are the first throughout the country to provide a new ...
• Highlights include new safety and efficacy data of Barrigel ™ rectal spacer, the first and only sculptable rectal spacer 1-3 • Teleflex to host Barrigel™ Educational Symposium featuring a physician ...
Real-world comparison of prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ). This ...
Prostate cancer is the second most common cancer for American men, yet receiving a diagnosis can feel unexpected. [1] While some people experience symptoms like increased frequency of difficulty ...
• Teleflex to host Barrigel™ Educational Symposium featuring a physician panel discussion on the Science of Personalized Spacing with Barrigel™ rectal spacer Barrigel™ rectal spacer is a Non-Animal ...
Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced ...